Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Liabilities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Total Liabilities for 7 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 52.6% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, down 52.6% year-over-year, with the annual reading at $44.0 million for FY2025, 52.6% down from the prior year.
  • Total Liabilities for Q4 2025 was $44.0 million at Pliant Therapeutics, down from $76.3 million in the prior quarter.
  • The five-year high for Total Liabilities was $99.8 million in Q3 2024, with the low at $11.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $50.3 million, with a median of $39.4 million recorded in 2022.
  • The sharpest move saw Total Liabilities crashed 82.88% in 2021, then surged 213.83% in 2022.
  • Over 5 years, Total Liabilities stood at $22.2 million in 2021, then skyrocketed by 68.22% to $37.3 million in 2022, then rose by 3.51% to $38.6 million in 2023, then skyrocketed by 140.73% to $92.9 million in 2024, then crashed by 52.6% to $44.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $44.0 million, $76.3 million, and $79.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.